TINO triple negative breast cancer: Risk of recurrence and adjuvant chemotherapy

Breast Journal

Volumn 15, Issue 5, 2009, Pages 454-460

  Kaplan, Henry G ^c   Malmgren, Judith A ^a,b   Atwood, Mary ^c  

^a HealthStat Consulting Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Early stage; Node negative; Triple negative

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE NEU; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RACE; RECURRENT DISEASE; STATISTICS; SURVIVAL; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; SURVIVAL ANALYSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 70449645182     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00789.x     Document Type: Article

References (24)

1. 1. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:1721-1728 (Pubitemid 46668532)
2. 2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434 (Pubitemid 47219710)
3. The NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer Guidelines (Version 2.2008). © 2008 National Comprehensive Cancer Network, Inc. Available at: http://www. nccn.org. (accessed 28 January 2008)
4. 4. Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 2007;103:197-208 (OncoDx® (Pubitemid 46789142)
5. 5. Kaklamani V. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Expert Rev Mol Diagn 2006;6:803-809 (OncoDx® (Pubitemid 44911030)
6. Buyse M, Loi S, vant Veer L, et al. TRANSBIG Consortium.. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-1192 (Mammaprint®)
7. 7. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-728 (Pubitemid 351264384)
8. 8. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. / Clin Oncol 2001;19:980-991 (Pubitemid 32176272)
9. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual (6th edn). New York: Springer, 2002.
10. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008;14:466-473
11. 11. Ryden L, Landberg G, Stal O, et al. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive information. Breast Cancer Res Treat 2008;109:351-357 (Pubitemid 351644858)
12. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:51526.
13. SPSS for Windows. Release 14.0.2. Chicago: SPSS Inc, 2006.
14. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
15. 15. Fisher B, Jeong J-H, Anderson S, Wolmark N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96:1823-1831 (Pubitemid 40089466)
16. 16. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657 (Pubitemid 46631305)
17. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281
18. Slamon D, Eirmann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trast- uxumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Paper presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 52. Available at: http://www. abstracts2view.com/sabcs06/view.php ?nu=SABCS06L-78 Accessed September 26,2007.
19. 19. Coon JS, Marcus E, Gupta-Bart S, et al. Amplification and overexpression of Topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-1067 (Pubitemid 35177356)
20. 20. Pritchard KI, Messersmith H, Elavathil L, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26:736-744 (Pubitemid 351264386)
21. 21. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCAl in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-1668 (Pubitemid 39585635)
22. 22. Altundaq K, Harputluoglu H, Aksoy S, et al. Potential chemotherapy options in the triple negative subtype of breast cancer. J Clin Oncol 2007;25:1294-1295 (Pubitemid 46640586)
23. Rugo HS, Thomas ES, Lee RK, et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabene has efficacy in ER/PR/HER2negative breast cancer resistant to anthracycline and taxanes. Breast Cancer Res Treat 2007;106(Suppl. 1):S270. Abstract 6069.
24. Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94(Suppl. 1):S6. Abstract 3.